Abstract:Acute myeloid leukemia (AML) is a prevalent hematological malignancy that exhibits a wide array of molecular abnormalities. Although traditional treatment modalities such as chemotherapy and allogeneic stem cell transplantation (HSCT) have become standard therapeutic approaches, a considerable number of patients continue to face relapse and encounter a bleak prognosis. The emergence of immune escape, immunosuppression, minimal residual disease (MRD), and other contributing factors collectively contribute to this challenge. Recent research has increasingly highlighted the notable distinctions between AML tumor microenvironments and those of healthy individuals. In order to investigate the potential therapeutic mechanisms, this study examines the intricate transformations occurring between leukemic cells and their surrounding cells within the tumor microenvironment (TME) of AML. This review classifies immunotherapies into four distinct categories: cancer vaccines, immune checkpoint inhibitors (ICIs), antibody-based immunotherapies, and adoptive T-cell therapies. The results of numerous clinical trials strongly indicate that the identification of optimal combinations of novel agents, either in conjunction with each other or with chemotherapy, represents a crucial advancement in this field. In this review, we aim to explore the current and emerging immunotherapeutic methodologies applicable to AML patients, identify promising targets, and emphasize the crucial requirement to augment patient outcomes. The application of these strategies presents substantial therapeutic prospects within the realm of precision medicine for AML, encompassing the potential to ameliorate patient outcomes.

Advances in the immunoregulation and cellular immunotherapy in myeloid leukemia

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

[Current Research Advance on Cellular Immunotherapy for Leukemia-Review].

T-cell Immune Suppression in Patients with Hematologic Malignancies: Clinical Implications

Immunotherapy in leukaemia

Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Current Advances in Immunotherapy for Acute Leukemia: an Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer

A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges

Progress of Immunotherapy for Acute Leukemia

[Research Progress of Cell Immunotherapy in Treatment of Hematological Malignancies-Review].

New Insights into Antigen Specific Immunotherapy for Chronic Myeloid Leukemia

Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia

Research Advance on the Immune Escape of Acute Myeloid Leukemia——Review

Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress

Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment

Research Advances in Nanomedicine, Immunotherapy, and Combination Therapy for Leukemia.

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Recent Advances in Immunotherapy of Acute Leukemia Via Chimeric Antigen Receptor-Engineered T Cells

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments